Summary latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H2 2020, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.
Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
Anti-Viral Therapeutics Market Report Overview Anti-Viral Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Anti-Viral Therapeutics market types and applications. It is a focused study on Anti-Viral Therapeutics market space...
Hereditary Angioedema Therapeutics Market Report Overview Hereditary Angioedema Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Hereditary Angioedema Therapeutics market types and applications. It is a focused study on...
“LONCASTUXIMAB TESIRINE- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse large B cell lymphoma in 7 Major Markets. A detailed picture of the LONCASTUXIMAB TESIRINE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United...
“Phesgo - Drug Insight and Market Forecast - 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Phesgo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
242 pages •
By The Business Research Company
• Dec 2020
CAR-T Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global CAR-T Therapy market. Description: Where is the largest and fastest growing market for the CAR-T therapy...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
Orexin Receptor Type 1 - Pipeline Review, H2 2020
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 15 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Orexin Receptor...
Illicit Drug Use
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.